Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570492 · ClinicalTrials.gov registry record · Phase 4
Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 474
- Enrollment target
NCT00570492 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 474 participants.
The verdict
NCT00570492, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 474 participants
- Enrollment target
Study Summary
The primary objective of this study is to characterize, as accurately as possible, the estimation of the difference in pre-pubescent growth velocities between subjects treated continuously for one year with FFNS 110mcg QD, the highest dose approved for pediatric use in the US, and placebo nasal spray as determined by stadiometry.
Interventions
- DRUG Placebo nasal spray
- DRUG Fluticasone furoate nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2007-11-26 |
| Est. Completion | 2011-03-17 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00570492
The ClinicalTrials.gov registry entry for NCT00570492 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo nasal spray is the first listed.
NCT00570492 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00570492 about?
NCT00570492 is a clinical study titled "Phase 4 Fluticasone Furoate Nasal Spray (VERAMYST) Long Term Pediatric Growth Study.". The primary objective of this study is to characterize, as accurately as possible, the estimation of the difference in pre-pubescent growth velocities between subjects treated continuously for one year with FFNS 110mcg QD, the highest dose approved for pediatric use in the US, and placebo nasal spra...
What is the current status of trial NCT00570492?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 474 participants. The study started on 2007-11-26. Estimated completion is 2011-03-17.
What interventions are being tested in trial NCT00570492?
The interventions under investigation include: Placebo nasal spray (DRUG), Fluticasone furoate nasal spray (DRUG).
Who is sponsoring clinical trial NCT00570492?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.